S.Biomedics Co., Ltd. (KOSDAQ:304360)
South Korea
· Delayed Price · Currency is KRW 34,200
+1,650 (5.07%)
At close: Dec 5, 2025
S.Biomedics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2017 |
| Operating Revenue | 16,964 | 13,734 | 13,108 | 12,113 | 8,868 | 5,319 | Upgrade
|
| Other Revenue | - | - | - | -0 | - | -0 | Upgrade
|
| Revenue | 16,964 | 13,734 | 13,108 | 12,113 | 8,868 | 5,319 | Upgrade
|
| Revenue Growth (YoY) | 30.26% | 4.77% | 8.22% | 36.59% | 66.72% | 6.09% | Upgrade
|
| Cost of Revenue | 9,329 | 7,027 | 6,555 | 6,002 | 4,549 | 4,022 | Upgrade
|
| Gross Profit | 7,634 | 6,707 | 6,554 | 6,111 | 4,319 | 1,298 | Upgrade
|
| Selling, General & Admin | 5,863 | 5,665 | 5,414 | 4,224 | 3,357 | 3,365 | Upgrade
|
| Research & Development | 7,556 | 5,850 | 6,508 | 5,489 | 5,525 | 5,559 | Upgrade
|
| Amortization of Goodwill & Intangibles | 7.91 | 5.39 | 5.06 | 9.07 | 9.49 | 7.23 | Upgrade
|
| Operating Expenses | 14,406 | 12,149 | 12,543 | 9,863 | 8,947 | 9,731 | Upgrade
|
| Operating Income | -6,772 | -5,442 | -5,989 | -3,752 | -4,628 | -8,433 | Upgrade
|
| Interest Expense | -795.15 | -795.15 | -883.54 | -727.42 | -674.93 | -514.96 | Upgrade
|
| Interest & Investment Income | 310.05 | 310.05 | 266.24 | 146.72 | 101.05 | 97.05 | Upgrade
|
| Currency Exchange Gain (Loss) | 83.95 | 83.95 | 39.53 | 17.21 | 91.56 | -16.89 | Upgrade
|
| Other Non Operating Income (Expenses) | -1,255 | -159.85 | -2,665 | -918.38 | -151.52 | 184.2 | Upgrade
|
| EBT Excluding Unusual Items | -8,428 | -6,003 | -9,232 | -5,234 | -5,262 | -8,684 | Upgrade
|
| Gain (Loss) on Sale of Investments | 76.12 | 76.12 | 92.61 | 23.87 | 0.24 | 89.31 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 5.49 | - | - | - | Upgrade
|
| Other Unusual Items | 169.48 | 169.48 | -0.48 | - | 12.82 | - | Upgrade
|
| Pretax Income | -8,183 | -5,757 | -9,134 | -5,210 | -5,249 | -8,594 | Upgrade
|
| Income Tax Expense | 104.25 | 63.79 | 123.24 | -455.23 | -6.59 | -4.55 | Upgrade
|
| Earnings From Continuing Operations | -8,287 | -5,821 | -9,258 | -4,755 | -5,242 | -8,590 | Upgrade
|
| Minority Interest in Earnings | -1,289 | -869.84 | -1,063 | -1,572 | -424.81 | 842.53 | Upgrade
|
| Net Income | -9,576 | -6,691 | -10,321 | -6,327 | -5,667 | -7,747 | Upgrade
|
| Net Income to Common | -9,576 | -6,691 | -10,321 | -6,327 | -5,667 | -7,747 | Upgrade
|
| Shares Outstanding (Basic) | 12 | 12 | 11 | 10 | 10 | 10 | Upgrade
|
| Shares Outstanding (Diluted) | 12 | 12 | 11 | 10 | 10 | 10 | Upgrade
|
| Shares Change (YoY) | 3.73% | 5.22% | 6.97% | 0.67% | 0.42% | 3.93% | Upgrade
|
| EPS (Basic) | -810.19 | -581.66 | -944.09 | -619.09 | -558.24 | -766.36 | Upgrade
|
| EPS (Diluted) | -810.19 | -581.66 | -944.09 | -619.09 | -558.24 | -766.36 | Upgrade
|
| Free Cash Flow | -7,681 | -4,890 | -7,996 | -12,501 | -3,762 | -5,620 | Upgrade
|
| Free Cash Flow Per Share | -649.82 | -425.15 | -731.44 | -1223.19 | -370.56 | -555.91 | Upgrade
|
| Gross Margin | 45.00% | 48.84% | 50.00% | 50.45% | 48.70% | 24.40% | Upgrade
|
| Operating Margin | -39.92% | -39.62% | -45.69% | -30.98% | -52.19% | -158.54% | Upgrade
|
| Profit Margin | -56.45% | -48.72% | -78.73% | -52.23% | -63.90% | -145.65% | Upgrade
|
| Free Cash Flow Margin | -45.28% | -35.61% | -61.00% | -103.20% | -42.42% | -105.65% | Upgrade
|
| EBITDA | -4,814 | -3,717 | -4,436 | -2,235 | -3,180 | -7,084 | Upgrade
|
| EBITDA Margin | -28.38% | -27.06% | -33.84% | -18.45% | -35.86% | -133.17% | Upgrade
|
| D&A For EBITDA | 1,958 | 1,725 | 1,553 | 1,517 | 1,448 | 1,349 | Upgrade
|
| EBIT | -6,772 | -5,442 | -5,989 | -3,752 | -4,628 | -8,433 | Upgrade
|
| EBIT Margin | -39.92% | -39.62% | -45.69% | -30.98% | -52.19% | -158.54% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.